Liposarcoma - Pipeline Review, H2 2016

  • ID: 3989572
  • Report
  • 162 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Amgen Inc
  • Cellceutix Corp
  • Eli Lilly and Company
  • Horizon Pharma Plc
  • Immune Design Corp
  • Merck & Co Inc
  • MORE
Liposarcoma - Pipeline Review, H2 2016

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Liposarcoma – Pipeline Review, H2 2016, provides an overview of the Liposarcoma (Oncology) pipeline landscape.

Liposarcoma is a malignant tumor of fatty tissue. Symptoms include noticeable lump or swelling, pain, weight loss and abdominal pain. Predisposing factors include age, chemical exposure and radiation exposure. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Liposarcoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Liposarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liposarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Liposarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 10, 3 and 2 respectively. Liposarcoma.

Liposarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Liposarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Liposarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Liposarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Liposarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Liposarcoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Liposarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Liposarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc
  • Cellceutix Corp
  • Eli Lilly and Company
  • Horizon Pharma Plc
  • Immune Design Corp
  • Merck & Co Inc
  • MORE
List of Tables

List of Figures

-Introduction

-Liposarcoma Overview

-Therapeutics Development

-Pipeline Products for Liposarcoma - Overview

-Liposarcoma - Therapeutics under Development by Companies

-Liposarcoma - Pipeline Products Glance

-Late Stage Products

-Clinical Stage Products

-Early Stage Products

-Liposarcoma - Products under Development by Companies

-Liposarcoma - Companies Involved in Therapeutics Development

-Adaptimmune Therapeutics Plc

-Amgen Inc

-Cellceutix Corp

-Eli Lilly and Company

-Horizon Pharma Plc

-Immune Design Corp

-Karyopharm Therapeutics Inc

-Merck & Co Inc

-Mirati Therapeutics Inc

-Novartis AG

-Pfizer Inc

-Liposarcoma - Therapeutics Assessment

-Assessment by Monotherapy Products

-Assessment by Target

-Assessment by Mechanism of Action

-Assessment by Route of Administration

-Assessment by Molecule Type

-Drug Profiles

-abemaciclib - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-AMG-232 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-CMB-305 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-everolimus - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-GSK-3377794 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-HDM-201 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-interferon gamma-1b - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-Kevetrin - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-palbociclib - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-pazopanib hydrochloride - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-pembrolizumab - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-ribociclib succinate - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-selinexor - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-sirolimus - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-sitravatinib - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-Vimo-101 - Drug Profile

-Product Description

-Mechanism Of Action

-R&D Progress

-Liposarcoma - Dormant Projects

-Liposarcoma - Discontinued Products

-Liposarcoma - Product Development Milestones

-Featured News & Press Releases

-Nov 09, 2016: Adaptimmune Announces Removal of Partial Clinical Hold in Myxoid/Round Cell Liposarcoma

-Aug 03, 2016: Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR T-cell Therapy in Myxoid Round Cell Liposarcoma

-Aug 03, 2016: Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR T-cell Therapy in Myxoid Round Cell Liposarcoma

-Appendix

-Methodology

-Coverage

-Secondary Research

-Primary Research

-Expert Panel Validation

-Contact Us

-Disclaimer

List of Tables

-Number of Products under Development for Liposarcoma, H2 2016

-Number of Products under Development by Companies, H2 2016

-Comparative Analysis by Late Stage Development, H2 2016

-Comparative Analysis by Clinical Stage Development, H2 2016

-Comparative Analysis by Early Stage Development, H2 2016

-Products under Development by Companies, H2 2016

-Liposarcoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016

-Liposarcoma - Pipeline by Amgen Inc, H2 2016

-Liposarcoma - Pipeline by Cellceutix Corp, H2 2016

-Liposarcoma - Pipeline by Eli Lilly and Company, H2 2016

-Liposarcoma - Pipeline by Horizon Pharma Plc, H2 2016

-Liposarcoma - Pipeline by Immune Design Corp, H2 2016

-Liposarcoma - Pipeline by Karyopharm Therapeutics Inc, H2 2016

-Liposarcoma - Pipeline by Merck & Co Inc, H2 2016

-Liposarcoma - Pipeline by Mirati Therapeutics Inc, H2 2016

-Liposarcoma - Pipeline by Novartis AG, H2 2016

-Liposarcoma - Pipeline by Pfizer Inc, H2 2016

-Assessment by Monotherapy Products, H2 2016

-Number of Products by Stage and Target, H2 2016

-Number of Products by Stage and Mechanism of Action, H2 2016

-Number of Products by Stage and Route of Administration, H2 2016

-Number of Products by Stage and Molecule Type, H2 2016

-Liposarcoma - Dormant Projects, H2 2016

-Liposarcoma - Discontinued Products, H2 2016

List of Figures

-Number of Products under Development for Liposarcoma, H2 2016

-Number of Products under Development by Companies, H2 2016

-Comparative Analysis by Clinical Stage Development, H2 2016

-Assessment by Monotherapy Products, H2 2016

-Number of Products by Top 10 Targets, H2 2016

-Number of Products by Stage and Top 10 Targets, H2 2016

-Number of Products by Top 10 Mechanism of Actions, H2 2016

-Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

-Number of Products by Routes of Administration, H2 2016

-Number of Products by Stage and Routes of Administration, H2 2016

-Number of Products by Molecule Types, H2 2016

-Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Adaptimmune Therapeutics Plc
  • Amgen Inc
  • Cellceutix Corp
  • Eli Lilly and Company
  • Horizon Pharma Plc
  • Immune Design Corp
  • Karyopharm Therapeutics Inc
  • Merck & Co Inc
  • Mirati Therapeutics Inc
  • Novartis AG
  • Pfizer Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll